Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | NSD2 | O96028 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.50 |
| ▸ | POLB | P06746 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | APAF1 | O14727 | 9/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241695 | 1.00 | DUSP3 (0.66) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2241690 | 1.00 | DUSP3 (0.66) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2777103 | 0.91 | KMT2A (0.55) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2777105 | 0.91 | KMT2A (0.55) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2777102 | 0.91 | KMT2A (0.55) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2778921 | 0.88 | NSD2 (0.66) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2241676 | 0.88 | DUSP3 (0.51) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2778924 | 0.88 | NSD2 (0.66) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2243963 | 0.88 | DUSP3 (0.51) | DUSP3NSD2KMT2APOLBMEN1 | |
| SCHEMBL2778917 | 0.88 | NSD2 (0.66) | DUSP3NSD2KMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | claimed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| US-8673910-B2 | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2014-03-18 | — | — | US | disclosed |
| US-8466157-B2 | Proteasome inhibitors having chymotrypsin-like activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010102286-A2 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201609-A1 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | PSMB7, PSMD7, PSMB6 | DUSP3 1256/4885NSD2 764/4885KMT2A 2094/4885 |
| US-20120142917-A1 | PROTEASOME INHIBITORS HAVING CHYMOTRYPSIN-LIKE ACTIVITY | PSMB4, PSME4, PSMB1 | DUSP3 3562/4885NSD2 1130/4885KMT2A 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.